向日葵被立案调查

Core Viewpoint - Zhejiang Sunflower Health Technology Co., Ltd. (Sunflower) is under investigation by the Zhejiang Securities Regulatory Bureau for misleading statements in its restructuring plan, which has raised market concerns about the actual production capacity and business model of the acquisition target [1][4]. Group 1: Restructuring Plan and Investigation - On September 22, 2025, Sunflower disclosed a restructuring plan involving the acquisition of 100% equity in Xipu Materials and 40% equity in Beid Pharmaceutical, along with raising supporting funds [4]. - The Zhejiang Securities Regulatory Bureau has initiated an investigation into Sunflower for potential misleading statements in the restructuring plan [1]. - The Shenzhen Stock Exchange issued a letter of concern to Sunflower regarding the actual production capacity of Xipu Materials and the operational status of its factories [4]. Group 2: Market Reaction and Financial Performance - Following the announcement of the restructuring plan, Sunflower's stock price peaked at 10.28 CNY but has since declined, closing at 6.20 CNY on January 14, 2026, representing a nearly 28% drop from its highest point [5]. - As of January 14, 2026, Sunflower's total market capitalization is reported at 8 billion CNY [5].